|
gptkbp:instanceOf
|
gptkb:drug
small molecule
Janus kinase inhibitor
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA45
|
|
gptkbp:brand
|
gptkb:Rinvoq
|
|
gptkbp:CASNumber
|
1310726-60-3
|
|
gptkbp:chemicalFormula
|
C17H19F3N6O
|
|
gptkbp:contraindication
|
severe hepatic impairment
active serious infection
|
|
gptkbp:developedBy
|
gptkb:AbbVie
|
|
gptkbp:eliminationHalfLife
|
8-14 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
upadacitinib
|
|
gptkbp:KEGGID
|
D10960
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
JAK1 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
380.37 g/mol
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:proteinBinding
|
52%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL3544943
7164398
DB15082
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
elevated liver enzymes
herpes zoster
upper respiratory tract infection
increased risk of infection
|
|
gptkbp:UNII
|
6X9OC3H4II
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
gptkb:atopic_dermatitis
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
ankylosing spondylitis
|
|
gptkbp:bfsParent
|
gptkb:JAK-STAT_signaling_pathway
gptkb:Rinvoq
gptkb:L04AC13
gptkb:JAK3
gptkb:DMARDs
|
|
gptkbp:bfsLayer
|
7
|